Liu JF, et al. - In this investigator-initiated phase 2 study, researchers determined the impacts of combining the MEK inhibitor trametinib and the AKT inhibitor GSK2141795 to achieve dual inhibition of PI3K and RAS signaling in patients with recurrent cervical cancer (n=14), focusing on best tumor response, progression-free survival, overall survival, and safety. Findings revealed the feasibility of the combination of trametinib and GSK2141795, but this treatment regimen needed dose modifications for adverse events. Minimal anti-cancer activity was noted even in cases with PI3K or RAS pathway changes. Early after the discontinuation of GSK2141795 development, the study was ended. Further development of this combination in cervical cancer was not supported.